{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:05:26Z","timestamp":1784016326866,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors, including PD-1 inhibitors such as sintilimab, have revolutionized cancer treatment but may induce immune-related adverse events (irAEs). Ocular irAEs, particularly severe corneal complications, are increasingly recognized but remain underreported, especially with sintilimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report a case of a patient in their 60\u00a0s with gastric adenocarcinoma who developed bilateral severe corneal ulcers following sintilimab therapy. A comprehensive review of literature on PD-1\/PD-L1 inhibitor-associated corneal lesions was conducted to contextualize this rare complication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patient presented with progressive ocular symptoms 3\u00a0weeks after initiating sintilimab. Despite topical anti-inflammatory and antimicrobial treatment, bilateral corneal ulcers progressed, culminating in corneal perforation of the right eye. Conservative medical management led to gradual healing and anterior chamber reformation. Literature review identified few similar cases, highlighting the rarity and severity of sintilimab-associated corneal toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the potential for severe, vision-threatening corneal complications following PD-1 inhibitor therapy. Early recognition, interdisciplinary collaboration, and timely intervention are critical to mitigate ocular morbidity. Ophthalmologists and oncologists should maintain high vigilance for ocular irAEs in patients receiving immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1857433","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:38:07Z","timestamp":1784014687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A case of severe bilateral corneal ulcer associated with sintilimab therapy: case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shancheng","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatol. Oxf."},{"key":"B3","first-page":"155864","article-title":"Exploring immune checkpoint inhibitors: focus on PD-1\/PD-L1 axis and beyond","volume-title":"Pathol Res Pract.","author":"Aden","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: Signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e940688","DOI":"10.12659\/ajcr.940688","article-title":"Corneal perforation in a patient treated with atezolizumab-bevacizumab combination therapy for unresectable hepatocellular carcinoma","volume":"24","author":"Alkharashi","year":"2023","journal-title":"Am. J. Case Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1080\/09273948.2025.2456647","article-title":"Corneal perforation associated with pembrolizumab - a case report with literature review","volume":"33","author":"Balasubaramaniam","year":"2025","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21767\/2471-8041.100044","article-title":"Bilateral uveitis and keratitis following Nivolumab treatment for metastatic melanoma","volume":"3","author":"Baughman","year":"2017","journal-title":"Med. Case Rep. Wilmingt."},{"key":"B8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and clinical patterns of ocular complications associated with Anti-PD-1\/PD-L1 anticancer immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am. J. Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"B10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/CJI.0000000000000224","article-title":"Autoimmune granulomatous inflammation of lacrimal glands and axonal neuritis following treatment with ipilimumab and radiation therapy","volume":"41","author":"Ileana Dumbrava","year":"2018","journal-title":"Journla Immunother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00262-024-03869-1","article-title":"Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer","volume":"74","author":"Ladjevardi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2016.10.008","article-title":"Corneal graft rejection in a patient treated with nivolumab for primary lung cancer","volume":"102","author":"Le Fournis","year":"2016","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.36401\/jipo-22-14","article-title":"Highlights on ocular toxicity of immune checkpoint inhibitors at a US tertiary cancer center","volume":"5","author":"Mazharuddin","year":"2022","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ICO.0000000000000724","article-title":"Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation","volume":"35","author":"Nguyen","year":"2016","journal-title":"Cornea"},{"key":"B16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/ico.0000000000002490","article-title":"Bilateral corneal perforation in a patient under Anti-PD1 therapy","volume":"40","author":"Ramaekers","year":"2021","journal-title":"Cornea"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102074","DOI":"10.1016\/j.ajoc.2024.102074","article-title":"Durvalumab-associated limbal stem cell deficiency and secondary corneal perforation","volume":"35","author":"Schumaier","year":"2024","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1758835921992989","article-title":"Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm","volume":"13","author":"Shahzad","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.4049\/jimmunol.179.6.3672","article-title":"The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival","volume":"179","author":"Shen","year":"2007","journal-title":"J. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2424611","DOI":"10.1080\/21645515.2024.2424611","article-title":"PD-1\/PD-L1 inhibitors related adverse events: a bibliometric analysis from 2014 to 2024","volume":"21","author":"Song","year":"2025","journal-title":"Hum. Vaccin Immunother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1167\/iovs.08-2536","article-title":"Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism","volume":"50","author":"Sugita","year":"2009","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/ICO.0000000000002372","article-title":"Bilateral corneal graft rejection associated with pembrolizumab treatment","volume":"39","author":"Vanhonsebrouck","year":"2020","journal-title":"Cornea"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/IIO.0000000000000263","article-title":"Immune checkpoint inhibitors in uveal and conjunctival melanoma","volume":"59","author":"Wierenga","year":"2019","journal-title":"Int. Ophthalmol. Clin."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.21037\/tcr-23-1952","article-title":"Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report","volume":"13","author":"Xiang","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1519082","DOI":"10.3389\/fphar.2025.1519082","article-title":"Immune-related adverse events with PD-1\/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients","volume":"16","author":"Yan","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e002119","DOI":"10.1136\/jitc-2020-002119","article-title":"Ocular adverse events in PD-1 and PD-L1 inhibitors","volume":"9","author":"Young","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e42490","DOI":"10.1097\/md.0000000000042490","article-title":"Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: a case report and literature review","volume":"104","author":"Zan","year":"2025","journal-title":"Med. Baltim."},{"key":"B31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1046\/j.1365-2796.2003.01074.x","article-title":"The cytokine network in sarcoidosis and its clinical relevance","volume":"253","author":"Ziegenhagen","year":"2003","journal-title":"J. Intern. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1857433\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:38:08Z","timestamp":1784014688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1857433\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":31,"alternative-id":["10.3389\/fphar.2026.1857433"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1857433","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1857433"}}